Advancing COVID-19 vaccines – avoiding different regulatory standards for different vaccines and need for open and transparent data sharing
The erratic ways by which the global scientific R&D, pharma and technology community conducted themselves during epidemics such as SARS-CoV-1, Ebola virus, MERS-CoV and others, the lack of co-operation and missed opportunities for filling important knowledge gaps and having an enhancing and multiplier effect, led to the establishment of the WHO R&D Blueprint and global strategy and preparedness plan (WHO, 2020a). The Blueprint leverages the successes and addresses the gaps in order for the world to be prepared for the next pandemic(s).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Eskild Petersen, Alimuddin Zumla Tags: Editorial Source Type: research
More News: COVID-19 | Ebola | Ebola Vaccine | Epidemics | Epidemiology | Infectious Diseases | MERS | Pandemics | Pharmaceuticals | SARS | Vaccines